One course versus two courses of recombinant alpha interferon in chronic C hepatitis
Part of the
Archives of Virology
book series (ARCHIVES SUPPL, volume 4)
Fifty-five patients with antibodies to HCV and chronic liver disease have been enrolled in the study. Thirty-four patients were treated with recombinant alpha interferon (IFN, 3 MU daily for 10 days followed by 3 MU twice/week for 3 months), and were compared to 21 untreated controls.
Alanine aminotransferase (ALT) normalization was observed in a significant proportion of treated patients (52.9%), but 66.6% of them experienced a relapse after discontinuation of the therapy. The evaluation of the early ALT behavior after the 10 days priming with daily IFN administration was useful in predicting the response.
The administration of a second IFN course with the same schedule and duration as the first course did not increase the efficacy of the treatment. Increased dosage and/or prolonged administration are probably required.
KeywordsBiochemical Remission Recombinant Immunoblot Assay Active Cirrhosis Recombinant Human Alpha Interferon Recombinant Interferon Alfa
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Di Bisceglie AM, Martin P, Kassianides C et al (1989) Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321: 1506–1510PubMedCrossRefGoogle Scholar
Davis GL, Baiart LA, Schiff ER et al (1989) Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. N Engl J Med 321: 1501–1506PubMedCrossRefGoogle Scholar
Saracco G, Rosina F, Torrani Cerenzia MR et al (1990) A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 11 [Suppl]: 43–49CrossRefGoogle Scholar
Ferenci P, Vogel W, Pristautz H et al (1990) One-year treatment of chronic non-A, non-B hepatitis with interferon alfa 2b. J Hepatol 11 [Suppl]: 50–53CrossRefGoogle Scholar
Jacyna MR, Brooks MG, Loke RHT et al (1989) Randomized controlled trial of interferon alpha (lymphoblastoid interferon) in chronic non-A, non-B hepatitis. Br Med J 298: 80–82CrossRefGoogle Scholar
Hoofnagle JH, Mullen KD, Jones DB et al (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med 315: 1575–1578PubMedCrossRefGoogle Scholar
Gomez-Rubio M, Porres JC, Castillo I et al (1990) Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group. J Hepatol 11 [Suppl]: 63–67CrossRefGoogle Scholar
Taliani G, Lecce R, Clementi C, Furlan C, De Bac C (1991) Antibodies to hepatitis C virus and response to Interferon treatment in non-A, non-B chronic hepatitis. J Hepatol 12: 264–265PubMedCrossRefGoogle Scholar